Day One Biopharmaceuticals Inc.

07/25/2024 | Press release | Distributed by Public on 07/24/2024 23:29

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.